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Abstract
Introduction: Idiopathic pulmonary arterial hypertension is defined as a group of diseases characterized by a progressive
increase in pulmonary vascular resistance that results in right heart failure and premature death. Although therapies exist
to improve hemodynamic instability and symptoms, there is no cure for pulmonary arterial hypertension and it remains a
life-threatening condition. A recent study performed in China reported, for the first time, the effect of pulmonary arterial
denervation on functional capacity and hemodynamics in patients with refractory idiopathic pulmonary arterial
hypertension.
Case presentation: We report a case of a 60-year-old white Brazilian man, with controlled hypertension and stage
2 obesity who complained of progressive fatigue with moderate to light exertion of approximately 1 year’s
duration. During this period, he underwent myocardial perfusion scintigraphy without evidence of obstructive
ischemic disease. He had no clinical evidence of systolic heart failure. He had undergone biological mitral valve
replacement 3 years previously for mitral valve stenosis and ablation of atrioventricular nodal reentry tachycardia 18
months previously. At the time of valve replacement, he had no reported evidence of pulmonary arterial
hypertension. His echocardiogram showed normal function of a mitral prosthesis, normal global left
ventricular systolic function (left ventricular ejection fraction 62 % measured using the Teichholz method), stage I
diastolic dysfunction, and a mean systolic pulmonary arterial blood pressure of 50 mmHg. In the 6-minute walk test, the
patient walked 104 meters. Catheterization of his right heart chambers and pulmonary arteries confirmed the diagnosis of
pulmonary hypertension. Electroanatomic reconstruction of the right ventricular outflow tract and pulmonary artery was
performed under direct fluoroscopic visualization, and a merger was made with a formatted image of cardiac
computed tomography angiography. Then we performed irrigated cardiac catheter ablation of the pulmonary
trunk.
Conclusions: At the patient’s 3-month follow-up, he showed improvement in functional class for fatigue on major
exertion, increased distance walked in the 6-minute walk test, and reductions in pressure of both the right cavities and
the pulmonary artery. Currently, with 6 months of clinical follow-up, the patient has maintained his functional
classification and is pedaling his bicycle.
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Introduction
Idiopathic pulmonary arterial hypertension is defined as a
group of diseases characterized by a progressive increase
in pulmonary vascular resistance that results in right heart
failure and premature death [1–7]. Recent therapeutic
advances have improved the treatment options, includ-
ing prostanoids, endothelin receptor antagonists, and
phosphodiesterase type 5 inhibitors [3–6, 8, 9]. The
pathogenesis of idiopathic pulmonary arterial hyperten-
sion is believed to be due to an imbalance between locally
produced vasodilators and vasoconstrictors [10]. Recent
studies have demonstrated that vascular wall remodeling
also contributes to elevated pulmonary vascular resistance
[11]. A meta-analysis of 23 randomized controlled trials
demonstrated a reduction in mortality of patients who
used targeted therapies approved for use in patients with
pulmonary arterial hypertension [10].
Case presentation
A 60-year-old white Brazilian man, with controlled hyper-
tension and stage 2 obesity presented to our institution
with a complaint of progressive fatigue with moderate to
light exertion of approximately 1 year’s duration. During
that period, he had undergone myocardial perfusion scin-
tigraphy without evidence of obstructive ischemic disease.
He had no clinical evidence of systolic heart failure. He
had undergone biological mitral valve replacement 3 years
previously for mitral valve stenosis and had undergone ab-
lation of atrioventricular nodal reentry tachycardia 18
months previously. At the time of valve replacement,
there was no reported evidence of pulmonary arterial
hypertension. The patient’s medication list included as-
pirin 100 mg/day, carvedilol 50 mg/day, atorvastatin 10
mg/day, and losartan 25 mg/day. His echocardiogram
showed normal function of a mitral prosthesis, global
left ventricular systolic function within normal limits (left
ventricular ejection fraction 62 % measured using the
Teichholz method), stage I diastolic dysfunction, and
mean pulmonary arterial systolic blood pressure of 50
mmHg. In the 6-minute walk test, the patient walked 104
meters (Table 1). Catheterization of his right heart cham-
bers and pulmonary arteries confirmed the diagnosis of
pulmonary hypertension (Table 2). During the follow-up
period, therapy with nifedipine and sildenafil was not toler-
ated secondary to orthostatic hypotension. The patient was
referred for radiofrequency ablation of the pulmonary
artery trunk for the treatment of refractory pulmonary
hypertension.
The procedure was performed in the catheterization la-
boratory with direct visualization using fluoroscopy and
radiopaque contrast dye. The patient remained under un-
conscious sedation. Catheterization of the right femoral
artery via the standard Seldinger technique was performed
using an 8-French valved short sheath after subcutaneous
injection of a local anesthetic. Subsequently, this sheath
was replaced with a steerable long sheath (Agilis®; St. Jude
Medical, St. Paul, MN, USA) using the standard over-the-
wire technique. Unfractionated heparin was administered
intravenously, targeting an activated coagulation time be-
tween 250 and 350 seconds. Electroanatomic reconstruc-
tion of both the right ventricular outflow tract and
pulmonary artery was performed using the EnSite Velocity
Cardiac Mapping System (St. Jude Medical) under direct
fluoroscopic visualization, and a merger was made with
the formatted image obtained by performing cardiac com-
puted tomography angiography (Fig. 1). The Agilis® sheath
was advanced into the right ventricular outflow tract just
before reaching the pulmonary valve. Through this long
sheath, we introduced an ablation catheter with an open
irrigated tip (St. Jude Medical). The parameters used for
each application according to our protocol were as follows:
power of 5 W, maximum temperature of 48 °C, 60-second
duration in each spot, maximum impedance variation
of 10 % from baseline values, and an irrigation flow
rate of 17 ml/minute, which created a circle in the
pulmonary artery trunk.
The patient was discharged the next morning. No note-
worthy changes before or after the procedure or before dis-
charge in the patient’s radiographic or echocardiographic
laboratory parameters were seen. The patient’s blood pres-
sure in both the right heart chambers and the pulmonary
artery were determined using catheterization before and at
3 and 6 months after the procedure. The results are shown
in Table 2. At the patient’s 3-month follow-up examination,
he showed an improvement in functional class for fatigue
with major exertion. He also demonstrated an increased
distance walked in the 6-minute walk test and reduction of
the pressures in both the right cavities and the pulmonary
artery. Currently, with 6 months of clinical follow-up, he
Table 1 6-Minute walk test results
Time point Distance
Baseline 104 m
3 months after ablation 250 m
6 months after ablation 302 m
Table 2 Right catheterization and mean systolic blood pressure
measurements before and after pulmonary artery ablation
Structures Baseline 3 months 6 months
Right pulmonary arterial pressure, mmHg 46 35 31
Left pulmonary arterial pressure, mmHg 46 33 30
Pulmonary artery trunk pressure, mmHg 47 36 29
Right ventricular pressure, mmHg 40 33 30
Right atrial pressure, mmHg 20 14 11
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has maintained his improvement in functional classifica-
tion and is pedaling his bicycle.
Discussion
There is no cure for pulmonary arterial hypertension, and
it remains a life-threatening disorder, though therapies
can improve patients’ symptoms, hemodynamics, and out-
comes [12]. A recent study performed in China reported,
for the first time, the effect of pulmonary arterial denerv-
ation on functional capacity and hemodynamics in pa-
tients with refractory idiopathic pulmonary arterial
hypertension [13].
Conclusion
The ablation of the pulmonary artery could be a promis-
ing tool in the future for the treatment of pulmonary
hypertension.
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